SCHEMBL4586328

SCHEMBL4586328

NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLRA1 P23415 1/20 0.43
SLC6A9 P48067 1/20 0.43
OR51E2 Q9H255 1/20 0.43
TERT O14746 1/20 0.40
ALDH1A1 P00352 5/20 0.38
EGLN1 Q9GZT9 2/20 0.38
ITGB1 P05556 1/20 0.37
ITGA5 P08648 1/20 0.37
MAPT P10636 3/20 0.37
LMNA P02545 2/20 0.37
TDP1 Q9NUW8 2/20 0.37
PTGS2 P35354 1/20 0.37
KDM4E B2RXH2 2/20 0.36
HIF1A Q16665 1/20 0.36
SLC22A6 Q4U2R8 1/20 0.36
SLC22A8 Q8TCC7 1/20 0.36
FAAH O00519 5/20 0.36
MMP2 P08253 1/20 0.35
PTPN1 P18031 1/20 0.35
CTH P32929 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL93766 1.00 GLRA1 (0.43) GLRA1SLC6A9OR51E2TERTALDH1A1
SCHEMBL391028 1.00 GLRA1 (0.43) GLRA1SLC6A9OR51E2TERTALDH1A1
SCHEMBL6674512 1.00 GLRA1 (0.43) GLRA1SLC6A9OR51E2TERTALDH1A1
SCHEMBL6674893 1.00 GLRA1 (0.43) GLRA1SLC6A9OR51E2TERTALDH1A1
SCHEMBL1402291 1.00 GLRA1 (0.43) GLRA1SLC6A9OR51E2TERTALDH1A1
SCHEMBL6130185 1.00 GLRA1 (0.43) GLRA1SLC6A9OR51E2TERTALDH1A1
Glycylglycylglycine SCHEMBL98565 1.00 GLRA1 (0.43) GLRA1SLC6A9OR51E2TERTALDH1A1
SCHEMBL6677616 1.00 GLRA1 (0.43) GLRA1SLC6A9OR51E2TERTALDH1A1
SCHEMBL391787 1.00 GLRA1 (0.43) GLRA1SLC6A9OR51E2TERTALDH1A1
SCHEMBL6120072 1.00 GLRA1 (0.43) GLRA1SLC6A9OR51E2TERTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1804835-A4 MULTIMERIC CONSTRUCTS GENZYME CORP (US) 2008-07-30 EP claimed
US-20080058505-A1 PTH functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules GARDELLA THOMAS J 2008-03-06 US claimed
EP-1804835-A2 MULTIMERIC CONSTRUCTS GENZYME CORPORATION (US) 2007-07-11 EP claimed
EP-1615998-A4 PLANT CELLS AND PLANTS WITH INCREASED TOLERANCE TO ENVIRONMENTAL STRESS BASF PLANT SCIENCE GMBH (DE) 2007-06-13 EP claimed
WO-2006031689-A2 MULTIMERIC CONSTRUCTS GENZYME CORPORATION (US) 2006-03-23 WO claimed
EP-1615998-A2 PLANT CELLS AND PLANTS WITH INCREASED TOLERANCE TO ENVIRONMENTAL STRESS BASF Plant Science GmbH (DE) 2006-01-18 EP claimed
WO-2004092349-A2 PLANT CELLS AND PLANTS WITH INCREASED TOLERANCE TO ENVIRONMENTAL STRESS BASF PLANT SCIENCE GMBH (DE) 2004-10-28 WO claimed
EP-1147133-A4 PTH FUNCTIONAL DOMAIN CONJUGATE PEPTIDES, DERIVATIVES THEREOF AND NOVEL TETHERED LIGAND-RECEPTOR MOLECULES GEN HOSPITAL CORP (US) 2003-02-12 EP claimed
EP-1147133-A2 PTH FUNCTIONAL DOMAIN CONJUGATE PEPTIDES, DERIVATIVES THEREOF AND NOVEL TETHERED LIGAND-RECEPTOR MOLECULES THE GENERAL HOSPITAL CORPORATION (US) 2001-10-24 EP claimed
WO-2000039278-A2 PTH FUNCTIONAL DOMAIN CONJUGATE PEPTIDES, DERIVATIVES THEREOF AND NOVEL TETHERED LIGAND-RECEPTOR MOLECULES THE GENERAL HOSPITAL CORPORATION (US) 2000-07-06 WO claimed
WO-2000011158-A1 GENETICALLY MODIFIED AND DIABETIC NON-HUMAN ANIMAL UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) 2000-03-02 WO claimed
US-20250051404-A1 FUSION PROTEINS FOR INHIBITING ANGIOGENESIS ALLGENESIS BIOTHERAPEUTICS INC. (TW) 2025-02-13 US disclosed
US-12152057-B2 Fusion proteins for inhibiting angiogenesis ALLGENESIS BIOTHERAPEUTICS INC. (TW) 2024-11-26 US disclosed
CN-111050790-B Combination therapy for the treatment of cancer by intravenous administration of recombinant MVA and antibodies 巴法里安诺迪克有限公司 2024-07-12 CN disclosed
CN-117956903-A Modified antimicrobial peptides 唐纳德丹福斯植物科学中心 2024-04-30 CN disclosed
WO-1999003882-A2 HUMAN LEUKOCYTE CALCIUM ACTIVATED POTASSIUM CHANNEL POLYPEPTIDE ZENECA LIMITED (GB) 1999-01-28 WO disclosed
EP-0851919-A1 ANTISENSE OLIGONUCLEOTIDE CHEMOTHERAPY FOR BENIGN HYPERPLASIA OR CANCER OF THE PROSTATE University of Massachusetts Worcester (US) 1998-07-08 EP disclosed
WO-1998011139-A1 SMALL AND INTERMEDIATE CONDUCTANCE, CALCIUM-ACTIVATED POTASSIUM CHANNELS AND USES THEREOF OREGON HEALTH SCIENCES UNIVERSITY (US) 1998-03-19 WO disclosed
CN-1162334-A Genes encoding signal recognition particle of aspergillus niger NOVO NORDISK BIOTECH INC (US) 1997-10-15 CN disclosed
WO-1997011170-A1 ANTISENSE OLIGONUCLEOTIDE CHEMOTHERAPY FOR BENIGN HYPERPLASIA OR CANCER OF THE PROSTATE WORCESTER FOUNDATION FOR BIOMEDICAL RESEARCH (US) 1997-03-27 WO disclosed